Peripheral T-Cell Lymphoma - Epidemiology Forecast - 2034

Key Highlights

• The total incident cases of PTCL in the 7MM were approximately 26,000 cases in 2023; these cases are estimated to increase by 2034.
• United States contributed to the largest incident population of PTCL, acquiring ~49% of the 7MM in 2023. Whereas, Japan accounted for around 32% incident population share in 2023.
• CD30 is universally expressed in sALCL and ~50% of non-sALCL subtypes. It is variably expressed in other subtypes and can be present in 58-64% of PTCL, 43-63% AITL, and 55% ATLL.
• The most Incident subtype is called PTCL-not-otherwise specified (PTCL-NOS) and is most frequently diagnosed in individuals living in North America and Europe. ALCL is common in North America and Europe, whereas, AITL the second most common subtype is found more often in Europe.

The “Peripheral T-cell Lymphoma (PTCL) - Market Insights, Epidemiology, and Market Forecast - 2034” report delivers an in-depth understanding of Peripheral T-cell Lymphoma, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Peripheral T-cell Lymphoma Understanding and Diagnosis

Peripheral T-cell Lymphoma Overview

PTCL is an uncommon and heterogeneous group of clinically aggressive types of non-Hodgkin lymphoma (NHL) that develop in mature white blood cells called “T cells” and “natural killer (NK) cells.” There are three types of lymphocytes, namely B lymphocytes (B cells), T lymphocytes (T cells), and natural killer cells (NK cells). NHL may arise in B cells or T cells, wherein the former is more common than the latter. NHLs may be indolent (slow-growing) or aggressive (fast-growing).

Peripheral T-cell Lymphoma Diagnosis

Most PTCLs are diagnosed by taking a small sample (a “biopsy”) of an enlarged lymph node and then examining the cells under a microscope. The cells in many subtypes of PTCLs look alike; therefore, making an accurate diagnosis may require the use of additional diagnostic tests, including blood tests, CT (computerized axial tomography), PET (positron emission tomography) scans, MRI (magnetic resonance imaging), and bone marrow biopsy. HIV testing is important since HIV is a risk factor for lymphoma and acute HIV infection can present with many of the same symptoms as PTCL, including fever, weight loss, and lymphadenopathy.

Peripheral T-cells Lymphoma Epidemiology

The Peripheral T-cells Lymphoma epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of Peripheral T-cells Lymphoma, total incident cases of Peripheral T-cells Lymphoma by Subtypes, total cases of Peripheral T-cells Lymphoma by stages, CD30 Expression in of Peripheral T-cells Lymphoma in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

• PTCL-NOS is more prevalent in the United States and Europe, and ATLL and NKTCL are more prevalent in Asia. ATLL was frequent in Japan but was not found in other Asian countries, whereas NKTCL made up 44% of the cases in Asia, excluding Japan. ALCL, ALK-positive, was most common in North America, whereas enteropathy-type PTCL was most common in Europe.
• Among EU4 and the UK, Germany accounted for the highest number of PTCL cases, followed by the UK, whereas Spain accounted for the lowest cases in 2023.
• Based on the location of the disease, PTCL is divided into four stages. The epidemiological estimates a higher proportion of PTCL cases was found in stages III-IV as compared to other stages I-II.
• In 2023, approximately 1,150 cases in Japan exhibited CD30 expression in ATLL.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Peripheral T-cell Lymphoma, explaining its causes, signs and symptoms, pathogenesis, and diagnostic approaches.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression.
• A detailed review of the Peripheral T-cell Lymphoma epidemiology, detailed assumptions, and rationale behind our approach is included in the report.
• A detailed review of current challenges in establishing the diagnosis.

Peripheral T-cell Lymphoma Report Insights

• Patient Population
• Patient population by gender, etiology, and age
• Country-wise Epidemiology Distribution

Peripheral T-cell Lymphoma Report Key Strengths

• Eleven Years Forecast
• 7MM Coverage
• Peripheral T-cell Lymphoma Epidemiology Segmentation

Peripheral T-cell Lymphoma Market Report Assessment

• Epidemiology Segmentation
• Current Diagnostic Practices

FAQs

• What are the disease risks and burdens of Peripheral T-cell Lymphoma? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Peripheral T-cell Lymphoma?
• What is the historical and forecasted Peripheral T-cell Lymphoma patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Which age group is the largest contributor in patients affected with Peripheral T-cell Lymphoma?
• What factors affect the increase in the patient number in later lines of Peripheral T-cell Lymphoma therapy?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges